N/A N=25 Effects of Short-term Growth Hormone in HIV-infected Patients
HIV Lipodystrophy
Primary: Overnight Mean Growth Hormone Secretion After 2 Weeks of Study Drug — 0.23; 0.07; 1.24 ng/mL — p=0.01
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=56 Growth Hormone Deficiency in Chronic Heart Failure: A Preliminary Trial
Heart Failure · Growth Hormone Deficiency · Ischemic Heart Disease
Primary: Peak VO2 — 14.5; 12.9 ml/kg/min
Phase 4 N=9 Growth Hormone and Endothelial Function in Children
Growth Hormone Deficiency · Panhypopituitarism · Short Stature
Primary: Reactive Hyperemic Response After 3 Months of Growth Hormone — 21.077 ml/dl min — p=0.644
Phase 3 N=42 Growth Hormone Therapy in Osteogenesis Imperfecta
Osteogenesis Imperfecta
Primary: Proportion of Subjects Who Met Criteria of Increase in Growth Rate Since Baseline. — 25 Participants
Phase 2 N=63 Recombinant Human Growth Hormone During Rehabilitation From Traumatic Brain Injury.
Traumatic Brain Injury
Primary: Functional Outcome 6 Months After Injury, as Measured by the Processing Speed Index — 82.5; 82.5 Processing speed index standardized scor
N/A N=56 Physiologic Growth Hormone Effects in HIV Lipodystrophy
AIDS · HIV Infections
Primary: Change in Visceral Adipose Tissue Area From Baseline to 18 Months — -22; -4 centimeters squared — p=0.049
Phase 2 N=35 Testosterone and Growth Hormone for Bone Loss in Men
Hypopituitarism · Hypogonadism · Growth Hormone Deficiency
Primary: MicroMRI-derived Structural (Bone Volume Fraction-BVF) of the Distal Tibia at Baseline and After One and Two Years of Treatment. — 0.112; 0.104; 0.119; 0.111 unitless
Phase 2 N=22 Growth Hormone Treatment in Patients With Aggrecan (ACAN) Deficiency
Short Stature
Primary: Height Standard Deviation Score — -2.52; -1.57; -1.19; -1.09 standard deviation score
Phase 3 N=113 Growth Hormone in Neuroendocrine Dysfunction With Severe Fibromyalgia Syndrome
Fibromyalgia
Primary: Percentage of Participants With Less Than 11 Tender Points at Month 6 — 20; 22 Percentage of participants
Phase 2 N=20 Trial of Growth Hormone Therapy in Pediatric Crohn's Disease
Crohn's Disease
Primary: Crohn's Disease Histologic Index of Severity (CDHIS) — 7; 8; 6; 8 scores on a scale
N/A N=15 Growth Hormone Treatment on Phosphocreatine Recovery in Obesity
Obese · Growth Hormone Secretion Abnormality
Primary: Phosphocreatine Recovery — 0.74 correlation coefficient — p=0.02
Phase 4 N=115 Growth Hormone Treatment for the Prevention of Short Stature in Young Girls With Turner Syndrome Before the Age of 4 Years
Turner's Syndrome
Primary: Height SDS at Year 4 — -1.35; -2.44 standard deviation score
Phase 2 N=33 Somatropin Therapy In Children Born Preterm But Appropriate For Gestational Age
Growth Hormone Therapy · Infant, Very Low Birth Weight
Primary: Change in Height Standard Deviation Score (SDS) After 1 Year — 1.099; 0.108 centimeters — p=<0.001
Phase 3 N=11 Effects of Growth Hormone on Cognition and Cerebral Metabolism in Adults With Growth Hormone Deficiency
Hypopituitarism
Primary: BOLD Signal Measured by Functional MRI Scan to Functional Connectivity Measured by fMRI
Phase 2 N=77 Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance
HIV-Associated Lipodystrophy Syndrome · Insulin Resistance · HIV Infections
Primary: Change in Insulin Sensitivity — 0.20; 1.44; -0.63; 0.14 uU*10^-4*min*ml^-1
N/A N=142 Growth Hormone, Cardiovascular Risk, and Visceral Adiposity
Obesity
Primary: HsCRP — -1.1; 0.5; -1.3; -0.3 mg/L
Phase 3 N=70 Efficacy and Safety of DA-3002 in Children With Idiopathic Short Stature
Idiopathic Short Stature
Primary: Annualized Height Velocity(cm/Year) After 26 Weeks — 10.68; 5.72 cm/year
Phase 3 N=43 Genotropin Treatment In Very Young Children Born Small For Gestational Age
Infant, Small for Gestational Age
Primary: Change From Baseline in Height Standard Deviation Score (SDS) at Month 24. — 1.63; 0.43 SDS — p=<0.001
Phase 3 N=11 Growth Hormone Use in Adults With Prader-Willi Syndrome
Prader-Willi Syndrome
Primary: Body Composition — 51.2; 48.5; 52.1 percentage of body fat — p=<0.05
Phase 3 N=98 Growth Hormone Treatment in Children Born Small for Gestational Age (SGA)
Foetal Growth Problem · Small for Gestational Age
Primary: Change in Height Standard Deviation Score (SDS) for Chronological Age (CA) at Week 260 - Subjects Received NN220 Treatment for 5 Years — -2.9488; -2.9047; 1.2066; 2.0247…
Phase 3 N=45 Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 Deficiency
Insulin-Like Growth Factor-1 Deficiency · Growth Disorders
Primary: Height Velocity From Pretreatment (Week 0) to Week 34 — 7.0 centimeters per year (cm/yr)
Phase 3 N=136 Prepubertal Children With Growth Failure Associated With Primary Insulin-Like Growth Factor-1 (IGF-1) Deficiency
Growth Disorders · Insulin-Like Growth Factor-1 Deficiency
Primary: Height Velocity During the First Year - Intent to Treat (ITT)Population — 5.2; 6.9; 7.7 cm/yr — p=<0.0001
Phase 3 N=208 Genotropin Treatment in Short Prepubertal Children With Intra-Uterine Growth Retardation
Growth Disorders · Intrauterine Growth Retardation
Primary: Change From Baseline in Annual Growth Rate Measured at 2 Years Following Treatment With Genotonorm — 3.07; 3.97; 2.84 cm/year — p=0.02922
N/A N=77 Study of Growth Hormone and Bone in Obesity
Obesity · Osteopenia
Primary: Bone Mineral Density — -0.015; -0.008 grams/cm^2
Phase 2 N=3 The Effect of GHRH Therapy on Myocardial Structure and Function in Congestive Heart Failure
Congestive Heart Failure
Primary: PP1- Serum IGF-1 Levels, DXA, Resting Metabolic Rate, Total Body Water, 3-D Echo, Cardiac MRI, Dobutamine Stress Echocardiogram, Ergometry, General Health Assessment…
Phase 4 N=15 Anterior Pituitary Hormone Replacement in Traumatic Brain Injury
Growth Hormone Deficiency · Traumatic Brain Injury
Primary: Maximum Oxygen Uptake at Baseline. — 29.0 mL/kg/min
Phase 2 N=20 Evaluation of rGH Therapy to Prevent Muscle Atrophy in Patients With ACL Tears
Rupture of Anterior Cruciate Ligament
Primary: Normative Isokinetic Knee Extension Strength, Measured in Newton Meters (Nm) at 26 Weeks Post-op — 0.881; 0.681 Nm — p=0.0498
Phase 3 N=54 Efficacy and Safety of Recombinant Human Growth Hormone on Height Velocity in Subjects With Idiopathic Short Stature
Growth Disorder · Idiopathic Short Stature
Primary: Height Velocity (Ht-V) — 12.02; 6.87 cm/year — p=<0.0001
Phase 2 N=22 Effect of Recombinant Human Growth Hormone (rhGH) on Abdominal Fat and Cardiovascular Risk in Obese Girls
Obesity
Primary: Change in Visceral and Subcutaneous Abdominal Adipose Tissue Over 6 Months — 57; 799; -111; 3634 mm^2 — p=0.70
N/A N=15 Effect of Short Term Growth Hormone Releasing Hormone in Healthy Men
Healthy Volunteers
Primary: Mean Overnight Growth Hormone — 1.2 mcg/L — p=<0.005